Exploring the role of circulating proteins in multiple myeloma risk: a Mendelian randomization study

Author:

Lee Matthew A.1,Burley Kate L.2,Hazelwood Emma L.2,Moore Sally3,Lewis Sarah J.2,Goudswaard Lucy J.2

Affiliation:

1. International Agency for Research on Cancer, World Health Organisation

2. University of Bristol

3. University Hospitals Bristol and Weston NHS Foundation Trust

Abstract

Abstract

Background Multiple myeloma (MM) is an incurable blood cancer with unclear aetiology. Proteomics, the high-throughput measurement of circulating proteins, is a valuable tool in exploring mechanisms of disease. We investigated the causal relationship between circulating proteins and MM risk, using two of the largest cohorts with proteomics data to-date. Methods We performed bidirectional two-sample Mendelian randomization (MR; forward MR = causal effect estimation of proteins and MM risk; reverse MR = causal effect estimation of MM risk and proteins). Summary statistics for plasma proteins were obtained from genome-wide association studies performed using SomaLogic (N = 35,559; deCODE) and Olink (N = 34,557; UK Biobank; UKB) proteomic platforms and for MM risk from a meta-analysis of UKB and FinnGen (case = 1,649; control = 727,247) or FinnGen only (case = 1,085; control = 271,463). Cis-SNPs associated with protein levels were used to instrument circulating proteins. We evaluated proteins for the consistency of directions of effect across MR analyses (with 95% confidence intervals not overlapping the null) and corroborating evidence from genetic colocalization. Results In the forward MR, 994 (SomaLogic) and 1,570 (Olink) proteins were instrumentable. 440 proteins were analysed in both deCODE and UKB; 302 (69%) of these showed consistent directions of effect in the forward MR. Seven proteins had 95% confidence intervals (CIs) that did not overlap the null in both forward MR analyses and did not have evidence for an effect in the reverse direction. MR evidence was strongest for the effect of dermatopontin on MM risk (deCODE) OR: 1.49 per SD higher protein levels, 95% CI 1.06–2.09; (UKB) OR: 1.47; 95% CI 1.14–1.90). Evidence from genetic colocalization did not meet our threshold for a shared causal signal between this protein and MM risk (h4 < 0.8). Conclusions Our results highlight seven circulating proteins which may be involved in MM risk. Although evidence from genetic colocalization suggests these associations may not be robust to horizontal pleiotropy, these proteins may be useful markers of MM risk. Future work should explore the utility of these proteins in disease prediction or prevention using proteomic data from patients with MM or precursor conditions.

Publisher

Springer Science and Business Media LLC

Reference63 articles.

1. CRUK. Cancer research UK: Myeloma statistics. 2023; Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/myeloma.

2. What is the significance of monoclonal gammopathy of undetermined significance?;Atkin C;Clin Med (Lond),2018

3. UK, C.R., Myeloma statistics. 2023.

4. Impact of CRAB Symptoms in Survival of Patients with Symptomatic Myeloma in Novel Agent Era;Nakaya A;Hematol Rep,2017

5. Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an;Stefano V;Haematologica,2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3